Gain Therapeutics (NASDAQ:GANX - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
Gain Therapeutics (NASDAQ:GANX - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.07. On average, analysts expect Gain Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Gain Therapeutics Stock Down 1.7 %
NASDAQ:GANX traded down $0.04 on Tuesday, reaching $2.00. The stock had a trading volume of 62,473 shares, compared to its average volume of 303,516. The stock has a market cap of $58.71 million, a P/E ratio of -1.80 and a beta of 0.17. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a 12-month low of $0.89 and a 12-month high of $3.19. The company has a 50-day moving average of $1.94 and a 200 day moving average of $2.05.
Analyst Ratings Changes
Several research firms have recently issued reports on GANX. HC Wainwright reiterated a "buy" rating and set a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, March 17th. Chardan Capital reiterated a "buy" rating and set a $6.00 price target on shares of Gain Therapeutics in a research report on Friday, March 28th. Finally, Scotiabank began coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Gain Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $8.20.
Read Our Latest Stock Analysis on Gain Therapeutics
Gain Therapeutics Company Profile
(
Get Free Report)
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gain Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gain Therapeutics wasn't on the list.
While Gain Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
